Evaluation of Th17-related cytokines and receptors in multiple sclerosis patients under interferon beta-1 therapy

ESENDAĞLI G., Kurne A. T., Sayat G., Kilic A. K., Guc D., KARABUDAK R.

JOURNAL OF NEUROIMMUNOLOGY, vol.255, pp.81-84, 2013 (SCI-Expanded) identifier identifier identifier

  • Publication Type: Article / Article
  • Volume: 255
  • Publication Date: 2013
  • Doi Number: 10.1016/j.jneuroim.2012.10.009
  • Journal Indexes: Science Citation Index Expanded (SCI-EXPANDED), Scopus
  • Page Numbers: pp.81-84
  • Keywords: Multiple sclerosis, IL-17, IL-23, IL-26, IL-17R, IL-23R, 17 CELLS, IL-23, ENCEPHALOMYELITIS, LYMPHOCYTES, IL-17, BLOOD
  • Hacettepe University Affiliated: Yes


Th17-related cytokines (IL-17, IL-23, and IL-26) and receptors (IL-17R and IL-23R) were evaluated in MS patients under immunomodulatory IFN-beta 1 therapy during a 2 year follow-up. Before the initiation of treatment, no significant difference was found in cytokine or receptor expression between controls and MS patients. Of the three cytokines evaluated, IL-26 was the highest in the patients' sera. The amount of IL-17 and CD13(+)IL-17R(+) cells was steadily decreased whereas IL-23 and IL-26 levels were gradually increased with IFN-beta 1 therapy. The patients in progressive phase had very high levels of IL-17. Th17-associated parameters should be considered in the immunomodulatory IFN-beta 1 therapy of MS. (C) 2012 Elsevier B.V. All rights reserved.